By Josh Beckerman

 

Reata Pharmaceuticals Inc. shares were recently down 30% to $38 after hours after the company received a negative opinion from a Food and Drug Administration advisory committee for its new drug application for bardoxolone methyl.

Reata shares were halted all day Wednesday.

 

Write to Josh Beckerman at josh.beckerman@wsj.com

 

(END) Dow Jones Newswires

December 08, 2021 19:10 ET (00:10 GMT)

Copyright (c) 2021 Dow Jones & Company, Inc.
Reata Pharmaceuticals (NASDAQ:RETA)
Historical Stock Chart
From Apr 2022 to May 2022 Click Here for more Reata Pharmaceuticals Charts.
Reata Pharmaceuticals (NASDAQ:RETA)
Historical Stock Chart
From May 2021 to May 2022 Click Here for more Reata Pharmaceuticals Charts.